{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:51:38Z","timestamp":1791114698246,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,2,19]],"date-time":"2009-02-19T00:00:00Z","timestamp":1235001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1741-7015-7-7","type":"journal-article","created":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T14:16:06Z","timestamp":1235744166000},"source":"Crossref","is-referenced-by-count":136,"title":["Recent developments in Alzheimer's disease therapeutics"],"prefix":"10.1186","volume":"7","author":[{"given":"Michael S","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,19]]},"reference":[{"key":"185_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126\/science.1072994.","journal-title":"Science"},{"key":"185_CR2","first-page":"S11","volume":"25","author":"F Gervais","year":"2004","unstructured":"Gervais F: GAG mimetics: potential to modify underlying disease process in AD. Neurobiol Aging. 2004, 25: S11-12.","journal-title":"Neurobiol Aging"},{"key":"185_CR3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","volume":"67","author":"PS Aisen","year":"2006","unstructured":"Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D: A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006, 67: 1757-1763. 10.1212\/01.wnl.0000244346.08950.64.","journal-title":"Neurology"},{"issue":"Suppl 16","key":"185_CR4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1092852900027061","volume":"13","author":"NR Relkin","year":"2008","unstructured":"Relkin NR: Current state of immunotherapy for Alzheimer's disease. CNS Spectr. 2008, 13 (Suppl 16): 39-41.","journal-title":"CNS Spectr"},{"key":"185_CR5","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1126\/science.1067568","volume":"295","author":"RB DeMattos","year":"2002","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002, 295: 2264-2267. 10.1126\/science.1067568.","journal-title":"Science"},{"key":"185_CR6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212\/01.WNL.0000159740.16984.3C.","journal-title":"Neurology"},{"key":"185_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2174\/156652407783220741","volume":"7","author":"X Chen","year":"2007","unstructured":"Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD: RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med. 2007, 7: 735-742. 10.2174\/156652407783220741.","journal-title":"Curr Mol Med"},{"key":"185_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1172\/JCI18162","volume":"112","author":"JL Eriksen","year":"2003","unstructured":"Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003, 112: 440-449.","journal-title":"J Clin Invest"},{"key":"185_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","volume":"7","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008, 7: 483-493. 10.1016\/S1474-4422(08)70090-5.","journal-title":"Lancet Neurol"},{"key":"185_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","volume":"65","author":"AS Fleisher","year":"2008","unstructured":"Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJl: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001\/archneur.65.8.1031.","journal-title":"Arch Neurol"},{"key":"185_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.nurt.2008.05.010","volume":"5","author":"MS Wolfe","year":"2008","unstructured":"Wolfe MS: Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics. 2008, 5: 391-398. 10.1016\/j.nurt.2008.05.010.","journal-title":"Neurotherapeutics"},{"key":"185_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.nurt.2008.05.007","volume":"5","author":"AK Ghosh","year":"2008","unstructured":"Ghosh AK, Gemma S, Tang J: beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics. 2008, 5: 399-408. 10.1016\/j.nurt.2008.05.007.","journal-title":"Neurotherapeutics"},{"key":"185_CR13","doi-asserted-by":"publisher","first-page":"18495","DOI":"10.1074\/jbc.M906994199","volume":"275","author":"J McLaurin","year":"2000","unstructured":"McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE: Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000, 275: 18495-18502. 10.1074\/jbc.M906994199.","journal-title":"J Biol Chem"},{"key":"185_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","volume":"7","author":"L Lannfelt","year":"2008","unstructured":"Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW: Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7: 779-786. 10.1016\/S1474-4422(08)70167-4.","journal-title":"Lancet Neurol"},{"key":"185_CR15","doi-asserted-by":"publisher","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","volume":"93","author":"CM Wischik","year":"1996","unstructured":"Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996, 93: 11213-11218. 10.1073\/pnas.93.20.11213.","journal-title":"Proc Natl Acad Sci USA"},{"key":"185_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nm0908-894","volume":"14","author":"T Gura","year":"2008","unstructured":"Gura T: Hope in Alzheimer's fight emerges from unexpected places. Nat Med. 2008, 14: 894-10.1038\/nm0908-894.","journal-title":"Nat Med"},{"key":"185_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1527-3458.2005.tb00053.x","volume":"11","author":"I Gozes","year":"2005","unstructured":"Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L: NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005, 11: 353-368.","journal-title":"CNS Drug Rev"},{"key":"185_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1124\/jpet.107.130526","volume":"325","author":"Y Matsuoka","year":"2008","unstructured":"Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS: A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008, 325: 146-153. 10.1124\/jpet.107.130526.","journal-title":"J Pharmacol Exp Ther"},{"key":"185_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"RS Doody","year":"2008","unstructured":"Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-215. 10.1016\/S0140-6736(08)61074-0.","journal-title":"Lancet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-7-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-7-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-7-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,18]],"date-time":"2017-06-18T13:12:08Z","timestamp":1497791528000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-7-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,19]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-7-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,19]]},"article-number":"7"}}